Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors; Multiple poster presentations at the 2022 Fa

  • Matthew Goldberg

Press/Media

Period23 Oct 2022 → 24 Oct 2022

Media coverage

12

Media coverage